Analgesic use in a Norwegian general population: change over time and high-risk use - The Tromsø Study

BMC Clinical Pharmacology

Anne Elise Eggen³  Ulla Dorte Mathisen²  Lars Slørdal¹  Per-Jostein Samuelsen³ 

[1] Department of Clinical Pharmacology, St. Olav University Hospital, Trondheim, Norway;Section of Nephrology, University Hospital of North Norway, Tromsø, Norway;Department of Community Medicine, UiT-The Arctic University of Norway, Tromsø, Norway

关键词: Pharmacoepidemiology;    Prevalence;    Contraindications;    Drug interactions;    NSAIDs;    Analgesics;   

Others  :  1218913
DOI  :  10.1186/s40360-015-0016-y

 received in 2015-01-26, accepted in 2015-05-24,  发布年份 2015

【 摘 要 】

Background

Increased use of analgesics in the population is a cause for concern in terms of drug safety. There is a paucity of population-based studies monitoring the change in use over time of both non-prescription (OTC) analgesics and prescription (Rx) analgesics. Although much is known about the risks associated with analgesic use, we are lacking knowledge on high-risk use at a population level. The purpose of this study was to estimate the prevalence of non-prescription and prescription analgesic use, change over time and the prevalence in the presence of potential contraindications and drug interactions in a general population.

Methods

A repeated cross-sectional study with data from participants (30–89 years) of the Tromsø Study in 2001–02 (Tromsø 5; N = 8039) and in 2007–08 (Tromsø 6; N = 12,981). Participants reported use of OTC and Rx analgesics and regular use of all drugs in the preceding four weeks. Change over the time period was analyzed with generalized estimating equations. The prevalence of regular analgesic use in persons with or without a clinically significant contraindication or drug interaction was determined in the Tromsø 6 population, and differences were tested with logistic regression.

Results

Analgesic use increased from 54 to 60 % in women (OR = 1.24, 95 % CI 1.15–1.32) and from 29 to 37 % in men (OR = 1.39, 95 % CI 1.27–1.52) in the time period; the increase was due to sporadic use of OTC analgesics. There was substantial regular use of analgesics in several of the contraindication categories examined; the prevalence of non-steroidal anti-inflammatory drugs was more than eight per cent among persons with chronic kidney disease, gastrointestinal ulcers, or high primary cardiovascular risk. About four per cent of the study population demonstrated at least one potential drug interaction with an analgesic drug.

Conclusions

The use of analgesics increased in the time period due to an increase in the use of OTC analgesics. Analgesic exposure in the presence of contraindications or drug interactions may put patients at risk. Public and prescriber awareness about clinically relevant contraindications and drug interactions with analgesics need to be increased.

【 授权许可】

   
2015 Samuelsen et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Association TNP. Facts and figures - pharmacies and pharmaceuticals in Norway 2012. Oslo. 2012.
• [2]Drug consumption in Norway 2009–2013. Norwegian Institute of Public Health, Oslo; 2014.
• [3]Eggen AE. The Tromso study: frequency and predicting factors of analgesic drug use in a free-living population (12–56 years). J Clin Epidemiol. 1993; 46(11):1297-304.
• [4]Antonov K, Isacson D. Use of analgesics in Sweden - the importance of sociodemographic factors, physical fitness, health and health-related factors, and working conditions. Soc Sci Med. 1996; 42(11):1473-81.
• [5]Isacson D, Bingefors K. Epidemiology of analgesic use: a gender perspective. Eur J Anaesthesiol. 2002; 19:5-15.
• [6]Paulose-Ram R, Hirsch R, Dillon C, Losonczy K, Cooper M, Ostchega Y. Prescription and non-prescription analgesic use among the US adult population: results from the third National health and nutrition examination survey (NHANES III). Pharmacoepidemiol Drug Saf. 2003; 12(4):315-26.
• [7]Porteous T, Bond C, Hannaford P, Sinclair H. How and why are non–prescription analgesics used in Scotland? Fam Pract. 2005; 22(1):78-85.
• [8]Hargreave M, Andersen TV, Nielsen A, Munk C, Liaw KL, Kjaer SK. Factors associated with a continuous regular analgesic use - a population-based study of more than 45,000 Danish women and men 18–45 years of age. Pharmacoepidemiol Drug Saf. 2010; 19(1):65-74.
• [9]Eggen AE. The use of controlled analgesics in a general population (15–59 years)- the influence of age, gender, morbidity, lifestyle and sociodemographic factors. Pharmacoepidemiol Drug Saf. 1996; 5(2):101-11.
• [10]Antonov KI, Isacson DG. Prescription and nonprescription analgesic use in Sweden. Ann Pharmacother. 1998; 32(4):485-94.
• [11]Saedder E, Brock B, Nielsen L, Bonnerup D, Lisby M. Identifying high-risk medication: a systematic literature review. Eur J Clin Pharmacol. 2014; 70(6):637-45.
• [12]Schjerning Olsen A-M, Fosbøl EL, Gislason GH. The impact of NSAID treatment on cardiovascular risk – insight from Danish observational data. Basic Clin Pharmacol Toxicol. 2014; 115(2):179-84.
• [13]de Abajo FJ, Gil MJ, Garcia Poza P, Bryant V, Oliva B, Timoner J, et al. Risk of nonfatal acute myocardial infarction associated with non-steroidal antiinflammatory drugs, non-narcotic analgesics and other drugs used in osteoarthritis: a nested case-control study. Pharmacoepidemiol Drug Saf. 2014;23(11):1128–38. doi:10.1002/pds.3617.
• [14]Schjerning Olsen A-M, Fosbøl EL, Lindhardsen J, Folke F, Charlot M, Selmer C, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011;123(20):2226–35. doi:10.1161/circulationaha.110.004671.
• [15]Aronson JK. Meyler’s side effects of analgesics and anti-inflammatory drugs. Elsevier Science, Amsterdam; Boston; London; 2010.
• [16]Huerta C, Castellsague J, Varas-Lorenzo C, García Rodríguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005; 45(3):531-9.
• [17]Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, et al. NSAID use and progression of chronic kidney disease. Am J Med. 2007;120(3):280e1–e7. doi:10.1016/j.amjmed.2006.02.015.
• [18]Baxter K, Preston C, editors. Stockley’s drug interactions. [online] London: Pharmaceutical Press; 2014
• [19]Gudin JA, Mogali S, Jones JD, Comer SD. Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use. Postgrad Med. 2013; 125(4):115-30.
• [20]Li L, Setoguchi S, Cabral H, Jick S. Opioid use for noncancer pain and risk of fracture in adults: a nested case-control study using the General practice research database. Am J Epidemiol. 2013; 178(4):559-69.
• [21]Tarantino G, Di Minno MND, Capone D. Drug-induced liver injury: is it somehow foreseeable? World J Gastroenterol. 2009; 15(23):2817-33.
• [22]Roberts E, Delgado Nunes V, Buckner S, Latchem S, Constanti M, Miller P, et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis. 2015. doi:10.1136/annrheumdis-2014-206914.
• [23]Adams R, Appleton S, Gill T, Taylor A, Wilson D, Hill C. Cause for concern in the use of non-steroidal anti-inflammatory medications in the community - a population-based study. BMC Fam Pract. 2011; 12(1):70. BioMed Central Full Text
• [24]Koffeman AR, Valkhoff VE, Çelik S, Jong GW, Sturkenboom MC, Bindels PJ, et al. High-risk use of over-the-counter non-steroidal anti-inflammatory drugs: a population-based cross-sectional study. Br J Gen Pract. 2014;64(621):e191–8. doi:10.3399/bjgp14X677815.
• [25]Silvani MC, Motola D, Poluzzi E, Bottoni A, De Ponti F, Vaccheri A, et al. Gastro-intestinal problems and concomitant medication in NSAID users: additional findings from a questionnaire-based survey in Italy. Eur J Clin Pharmacol. 2006;62(3):235–41. doi:10.1007/s00228-005-0078-7.
• [26]Stosic R, Dunagan F, Palmer H, Fowler T, Adams I. Responsible self-medication: perceived risks and benefits of over-the-counter analgesic use. Int J Pharm Pract. 2011; 19(4):236-45.
• [27]Wilcox CM, Cryer B, Triadafilopoulos G. Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal antiinflammatory drugs. J Rheumatol. 2005; 32(11):2218-24.
• [28]Jacobsen BK, Eggen AE, Mathiesen EB, Wilsgaard T, Njolstad I. Cohort profile: the Tromso study. Int J Epidemiol. 2012; 41(4):961-7.
• [29]Eggen AE, Mathiesen EB, Wilsgaard T, Jacobsen BK, Njølstad I. The sixth survey of the Tromsø study (Tromsø 6) in 2007–08: collaborative research in the interface between clinical medicine and epidemiology: study objectives, design, data collection procedures, and attendance in a multipurpose population-based health survey. Scand J Public Health. 2013; 41(1):65-80.
• [30]Hallan SI, Coresh J, Astor BC, Asberg A, Powe NR, Romundstad S, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol. 2006;17(8):2275–84. doi:10.1681/asn.2005121273.
• [31]Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro IIIAF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12. doi:10.7326/0003-4819-150-9-200905050-00006.
• [32]Selmer R, Lindman AS, Tverdal A, Pedersen JI, Njolstad I, Veierod MB. Model for estimation of cardiovascular risk in Norway. Tidsskr Nor Laegeforen. 2008; 128(3):286-90.
• [33]The Norwegian Directorate of Health. National guideline on individual primary prevention of cardiovascular disease. 2009. Available at: http://www.helsedirektoratet.no/.
• [34]Statistics Norway. Population, by sex and age (table 10211). Available at: http://www.ssb.no/.
• [35]Fredheim OM, Skurtveit S, Breivik H, Borchgrevink PC. Increasing use of opioids from 2004 to 2007 - pharmacoepidemiological data from a complete national prescription database in Norway. Eur J Pain. 2010; 14(3):289-94.
• [36]Hamunen K, Paakkari P, Kalso E. Trends in opioid consumption in the Nordic countries 2002-2006. Eur J Pain. 2009; 13(9):954-62.
• [37]Ruscitto A, Smith BH, Guthrie B. Changes in opioid and other analgesic use 1995–2010: Repeated cross-sectional analysis of dispensed prescribing for a large geographical population in Scotland. Eur J Pain. 2014.
• [38]Carlsten A, Wennberg M, Bergendal L. The influence of Rx-to-OTC changes on drug sales. Experiences from Sweden 1980–1994. J Clin Pharm Ther. 1996; 21(6):423-30.
• [39]Plantinga L, Grubbs V, Sarkar U, Hsu CY, Hedgeman E, Robinson B, et al. Nonsteroidal anti-inflammatory drug use among persons with chronic kidney disease in the United States. Ann Fam Med. 2011;9(5):423–30. doi:10.1370/afm.1302.
• [40]Mellbye A, Svendsen K, Borchgrevink PC, Skurtveit S, Fredheim OMS. Concomitant medication among persistent opioid users with chronic non-malignant pain. Acta Anaesthesiol Scand. 2012; 56(10):1267-76.
• [41]Nielsen MW, Søndergaard B, Kjøller M, Hansen EH. Agreement between self-reported data on medicine use and prescription records vary according to method of analysis and therapeutic group. J Clin Epidemiol. 2008; 61(9):919-24.
• [42]Loo RL, Chan Q, Brown IJ, Robertson CE, Stamler J, Nicholson JK, et al. A comparison of self-reported analgesic use and detection of urinary ibuprofen and acetaminophen metabolites by means of metabonomics: The INTERMAP study. Am J Epidemiol. 2012;175(4):348–58. doi:10.1093/aje/kwr292.
• [43]Lewis JD, Strom BL, Kimmel SE, Farrar J, Metz DC, Brensinger C, et al. Predictors of recall of over-the-counter and prescription non-steroidal anti-inflammatory drug exposure. Pharmacoepidemiol Drug Saf. 2006;15(1):39–45. doi:10.1002/pds.1134.